Prognostic evaluation of Ki67 and derived neutrophil-lymphocyte ratio in patients with nasopharyngeal carcinoma

doi:10.3760/cma.j.issn.1673-422X.2018.12.002

Abstract

Abstract: ObjectiveTo investigate the prognostic value of Ki67 and derived neutrophil to lymphocyte ratio (dNLR) in clinical outcomes of patients with nasopharyngeal carcinoma. MethodsA total of 180 patients with undifferentiated nasopharyngeal carcinoma confirmed by pathology from January 2011 to June 2015 in our hospital were enrolled. The neutrophil count and white blood cell count before radiotherapy and chemotherapy were collected, and dNLR was calculated. The positive rate of Ki67 in tumor tissues was detected by immunohistochemistry. The predictive values of Ki67 positive rate and dNLR on the overall survival (OS) rate and progression free survival (PFS) rate were evaluated. ResultsThe 3year OS rate prediction thresholds for patients with nasopharyngeal carcinoma by Ki67 and dNLR were 73.5% and 2.21, respectively, which assessed by receiver operating characteristic (ROC) curve. The proportion of TNM ⅢⅣ stage in patients with Ki67≥73.5% was higher than that in Ki67<73.5% (100% vs. 89.7%, χ2=5.529, P=0.019); the proportion of T34 stage in dNLR≥2.21 was higher than that in dNLR<2.21 (91.1% vs. 75.0%, χ2=6.228, P=0.013), and the proportion of TNM ⅢⅣ stage in the dNLR≥2.21 group was higher than that in the dNLR<2.21 group (100% vs. 90.3%, χ2=4.355, P=0.037). Multivariate Cox regression analysis indicated that Ki67≥73.5% (HR=3.011, 95%CI: 1.8744.982, P<0.001) and dNLR≥2.21 (HR=2.234, 95%CI: 1.2743.382, P=0.001) were independent risk factors for OS in patients with nasopharyngeal carcinoma, while Ki67≥73.5% (HR=2.842, 95%CI: 2.0554.337, P<0.001) and dNLR≥2.21 (HR=2.086, 95%CI: 1.4522.983, P<0.001) were also independent risk factors for PFS in patients with nasopharyngeal carcinoma. Patients were divided into highrisk group, mediumrisk group and lowrisk group combined with Ki67 and dNLR, the 3year OS rates were 20.0%, 85.7% and 95.3% respectively, and the 3year PFS rates were 12.0%, 78.6% and 89.4% respectively, with statistical differences (χ2=15.521, P<0.001; χ2=15.849, P<0.001). ConclusionKi67 and dNLR can effectively predict OS and PFS in patients with nasopharyngeal carcinoma, combined with Ki67 and dNLR can prognose stratification of patients with nasopharyngeal carcinoma.

Key words: Nasopharyngeal neoplasms, Prognosis;, Ratio of derived neutrophils to lymphocytes, Ki67

Xu Xiang, He Qingwen, Xiao Caiwen. Prognostic evaluation of Ki67 and derived neutrophil-lymphocyte ratio in patients with nasopharyngeal carcinoma[J]. Journal of International Oncology, 2018, 45(12): 711-715.

References

［1］ Lee AW, Ma BB, Ng WT, et al. Management of nasopharyngeal carcinoma: current practice and future perspective［J］. J Clin Oncol, 2015, 33(29): 33563364. DOI: 10.1200/JCO.2015.60.9347. ［2］中国抗癌协会鼻咽癌专业委员会, 李金高, 陈晓钟, 等. 鼻咽癌复发、转移诊断专家共识［J］. 中华放射肿瘤学杂志, 2018, 27(1): 715. DOI: 10.3760/cma.j.issn.10044221.2018.01.002. ［3］陈梦云, 张翠翠, 轩菡, 等. Ki67在肿瘤中的表达及其临床指导意义［J］. 现代生物医学进展, 2015, 15(16): 31933196. DOI: 10.13241/j.cnki.pmb.2015.16.049. ［4］ Liao LJ, Hsu WL, Wang CT, et al. Prognostic impact of pretreatment neutrophiltolymphocyte ratio (NLR) in nasopharyngeal carcinoma: a retrospective study of 180 Taiwanese patients［J］. Clin Otolaryngol, 2018, 43(2): 463469. DOI: 10.1111/coa.12992. ［5］钟秋璐, 李龄, 曲颂, 等. 局部晚期鼻咽癌IMRT联合化疗±靶向治疗疗效与安全性对比［J］. 中华放射肿瘤学杂志, 2016, 25(10): 10381043. DOI: 10.3760/cma.j.issn.10044221.2016.10.003. ［6］张继屏, 范静平, 邓月, 等. Ki67和nm23蛋白在鼻咽癌中的表达及临床意义［J］. 中国眼耳鼻喉科杂志, 2015, 15(1): 2024. DOI: 10.14166/j.issn.16712420.2015.01.007. ［7］ Zhao Y, Shen L, Huang X, et al. High expression of Ki67 acts a poor prognosis indicator in locally advanced nasopharyngeal carcinoma［J］. Biochem Biophys Res Commun, 2017, 494(12): 390396. DOI: 10.1016/j.bbrc.2017.09.118. ［8］ He QY, Jin F, Li YY, et al. Prognostic significance of downregulated BMAL1 and upregulated Ki67 proteins in nasopharyngeal carcinoma［J］. Chronobiol Int, 2018, 35(3): 348357. DOI: 10.1080/07420528.2017.1406494. ［9］钟丽婷, 彭卫卫. 血液标志物对鼻咽癌预后的研究进展［J］. 广东医学, 2017, 38(19): 30523054. DOI: 10.3969/j.issn.10019448.2017.19.037. ［10］ Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumourinfiltrating lymphocytes in cancer: a systematic review with metaanalysis［J］. Br J Cancer, 2011, 105(1): 93103. DOI: 10.1038/bjc.2011.189. ［11］ He JR, Shen GP, Ren ZF, et al. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma［J］. Head Neck, 2012, 34(12): 17691776. DOI: 10.1002/hed.22008. ［12］ Proctor MJ, Mcmillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer［J］. Br J Cancer, 2012, 107(4): 695699. DOI: 10.1038/bjc.2012.292. ［13］ Gomez D, Morrisstiff G, Toogood GJ, et al. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma［J］. J Surg Oncol, 2010, 97(6): 513518. DOI: 10.1002/jso.21001.

[1]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[2]	Gu Anqin, Long Jinhua, Jin Feng. Clinical research progress of immunotherapy for nasopharyngeal carcinoma [J]. Journal of International Oncology, 2023, 50(5): 299-303.
[3]	Chen Fangming, Cai Yuanyuan, Li Han, Wang Xiaoli, Kan Hongxing, Li Yang, Hao Furong, Wang Mingchen. Prognostic differences of nasopharyngeal carcinoma patients treated with intensity-modulated radiothe-rapy with different T staging of the seventh and eighth edition of the UICC staging system [J]. Journal of International Oncology, 2021, 48(9): 515-522.
[4]	Peng Ya, Liu An, Liu Huowang. Inhibitory effect and mechanism of PSD-007 photodynamic therapy on human nasopharyngeal carcinoma transplanted tumors in nude mice [J]. Journal of International Oncology, 2021, 48(3): 136-142.
[5]	Zhu Lei, Huang Jianbo. Effects of Epstein-Barr virus DNA load and different treatment methods on the therapeutic effect and prognosis of stage Ⅲ nasopharyngeal carcinoma [J]. Journal of International Oncology, 2021, 48(2): 74-79.
[6]	Luo Wenxiao, Wu Dehua, Cai Longmei. Prognostic values of immune efficacy biomarkers in the treatment of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2021, 48(12): 743-746.
[7]	Yang Minghui, Jin Feng. Value of 3D-ASL, MRS and DTI in the diagnosis and treatment of radiation-induced temporal lobe injury of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2020, 47(9): 550-554.
[8]	Yang Chao, Wang Jianbo, Zhang Juhong, Wang Jialong. Overexpression of miR-125 inhibits proliferation and invasion of nasopharyngeal carcinoma cells by down-regulating FGF-2 [J]. Journal of International Oncology, 2020, 47(5): 257-263.
[9]	Shen Jianjun. Treatment of local recurrenct nasopharyngeal carcinoma after radiotherapy [J]. Journal of International Oncology, 2020, 47(4): 227-230.
[10]	Zhou Yuanyuan, Li Jing. Clinical practice value of hematological inflammation biomarkers in nasopharyngeal carcinoma [J]. Journal of International Oncology, 2019, 46(8): 492-495.
[11]	Zhou Ping, Chen Weisi, Zhang Shuang, Lin Bing, Pan Tao, Liu Sha. Observation of efficacy of paclitaxel with concurrent radiotherapy in the treatment for nasopharyngeal carcinoma patients with liver metastasis [J]. Journal of International Oncology, 2019, 46(6): 327-330.
[12]	Li Zhe，Xing Yanke，Li Baosheng. Curative effect analysis of different clinical characteristics and treatment modalities for primary esophageal small cell carcinoma [J]. Journal of International Oncology, 2019, 46(3): 129-134.
[13]	Peng Yancai, Hao Dengrong. Expression and clinical significance of ribosome-binding protein 1 in esophageal carcinoma [J]. Journal of International Oncology, 2019, 46(11): 668-672.
[14]	CHEN Jiong-Yu, ZHUANG Yi-Xuan, ZHUANG Shan-Shan, PENG Lin. Effects of osthole on the proliferation, invasion and migration of nasopharyngeal carcinoma cells CNE2 [J]. Journal of International Oncology, 2018, 45(8): 453-459.
[15]	LAI Shi-Jia, ZHAO De-An, SUN Yong-Ming. Expression and clinical significance of serum microRNA663 in nasopharyngeal carcinoma patients [J]. Journal of International Oncology, 2018, 45(8): 460-464.